Correction of hyperphosphataemia associated with chronic renal failure in patients undergoing dialysis.
Athersys, Inc. announced that its partner, Helios K.K. (Healios), has reported topline results for its Japan ischemic stroke study, TREASURE.
Bristol-Myers Squibb K.K. announced that it has received approval in Japan for Breyanzi (generic name: lisocabtagene maraleucel; liso-cel), a CD19-targeting chimeric antigen receptor (CAR) T cell therapy (gene-modified autologous therapy), allowing its use in the second-line treatment of relapsed or refractory large B-cell lymphoma (LBCL), regardless of whether autologous hematopoietic stem-cell transplantation is intended.
Purpose:The findings from the observational studies comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) for atrial fibrillation (AF) and venous...